Navigating the CMS 14-Day Rule in Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.
Dr. Alex Adjei discusses how the standard of care for cancer patients has improved overt he last few years, but there is still a great need for new treatments designed to help a broader range of cancer patients.
Richard Parker, MD, provides an overview of this condition, which is common on patients with carcinoid syndrome.